ADC Therapeutics — Q4 2026 Earnings Summary

ADC Therapeutics announced new data from its ZYNLONTA clinical program to be presented at the 68th ASH Annual Meeting, featuring five oral presentations and multiple posters. Updated results from the Phase 1b LOTIS-7 study showed an 88.7% overall response rate and 75.3% complete response rate for ZYNLONTA combined with glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma. A Phase 2 investigator-initiated trial demonstrated a 93% overall response rate and 74.4% complete response rate for ZYNLONTA monotherapy in relapsed or refractory marginal zone lymphoma. Additionally, full results from the Phase 3 LOTIS-5 study indicated a statistically significant improvement in progression-free survival for ZYNLONTA plus rituximab compared to R-GemOx in the same lymphoma population.